Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013959 | 0.88 | HTT (0.59) | HTTALDH1A1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL1014528 | 0.84 | HTT (0.54) | HTTALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1017258 | 0.82 | HRH3 (0.51) | ALDH1A1SMN1; SMN2HIF1AEPAS1NPC1 | |
| SCHEMBL15323477 | 0.82 | L3MBTL1 (0.55) | HTTALDH1A1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL16884088 | 0.82 | HTT (0.76) | HTTALDH1A1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL4145433 | 0.81 | HTT (0.66) | HTTALDH1A1SMN1; SMN2LMNAPDE4B | |
| SCHEMBL12858537 | 0.80 | ALDH1A1 (0.48) | HTTALDH1A1SMN1; SMN2HIF1AEPAS1 | |
| SCHEMBL13634492 | 0.80 | SMN1; SMN2 (0.50) | HTTALDH1A1SMN1; SMN2HIF1AEPAS1 | |
| SCHEMBL13634176 | 0.78 | NOS1 (0.50) | HTTALDH1A1SMN1; SMN2HIF1AEPAS1 | |
| SCHEMBL6708339 | 0.78 | NPC1 (0.57) | HTTALDH1A1SMN1; SMN2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272835-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | CCL11, CCR1, CCR10 | HTT 4437/4885ALDH1A1 2564/4885KMT2A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.